Double-blind, 12-center RCT of 230 patients with chronic lateral epicondylar tendinopathy who had failed conventional therapy. Compares extensor tendon needling plus leukocyte-enriched PRP (type 1A) versus needling plus bupivacaine alone, with follow-up to 24 weeks. Asks whether PRP adds meaningful clinical benefit beyond the needling procedure itself.
The key question this paper answers is not whether PRP works, but when it works. At 12 weeks, PRP looks no different from needling alone — a finding that has been misused to dismiss PRP entirely.
The 24-week data tell a different story. When a patient with chronic tennis elbow has failed steroids, PT, and NSAIDs, PRP-augmented needling produces an 84% success rate vs 68% for needling alone, with treatment failure cut in half.
Counsel patients explicitly: improvement from PRP may not be apparent until 6 months post-injection. A patient who reports no benefit at 3 months has not yet reached the timeframe where PRP separates from control.
This trial also establishes the Mishra PRP classification system (types 1-4, based on leukocyte content and activation status). Results are specific to type 1A (leukocyte-enriched, unactivated) and cannot be extrapolated to other PRP formulations.
Double-blind, 12-center RCT of 230 patients with chronic lateral epicondylar tendinopathy who had failed conventional therapy. Compares extensor tendon needling plus leukocyte-enriched PRP (type 1A) versus needling plus bupivacaine alone, with follow-up to 24 weeks. Asks whether PRP adds meaningful clinical benefit beyond the needling procedure itself.
The key question this paper answers is not whether PRP works, but when it works. At 12 weeks, PRP looks no different from needling alone — a finding that has been misused to dismiss PRP entirely.
The 24-week data tell a different story. When a patient with chronic tennis elbow has failed steroids, PT, and NSAIDs, PRP-augmented needling produces an 84% success rate vs 68% for needling alone, with treatment failure cut in half.
Counsel patients explicitly: improvement from PRP may not be apparent until 6 months post-injection. A patient who reports no benefit at 3 months has not yet reached the timeframe where PRP separates from control.
This trial also establishes the Mishra PRP classification system (types 1-4, based on leukocyte content and activation status). Results are specific to type 1A (leukocyte-enriched, unactivated) and cannot be extrapolated to other PRP formulations.